This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good day, ladies and gentlemen, and welcome to the Brainstorm Cell Therapeutics third quarter 2021 earnings call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Michael Wood of LifeSci Advisors. Sir, the floor is yours.
spk13: Good morning, and thank you for joining us. Before we begin the opening remarks, I'd like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2021 and beyond, the safety and clinical effectiveness of the Neuron technology platform, clinical trials of neuron and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support the business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time to time in its filings with the SEC. The company's results may differ materially from those projected on today's call. the company undertakes no obligation to publicly update any forward-looking statements. Joining me on the call today will be Haim Leibowitz, President and CEO of Brainstorm, Ala Patlis, Interim Chief Financial Officer, and in addition, Dr. Stacey Lindberg, Executive VP and Chief Development Officer, Dr. Ralph Curran, President and Chief Medical Officer, and Dr. David Setburn, Executive VP and Chief Operating Officer, will also be on the call and will be available to answer questions during the Q&A session. So I'd now like to turn the call over to Mr. Leibowitz. Please go ahead.
spk12: Thanks, Michael. Thanks to all listening for joining us to discuss our third quarter financial results and corporate highlights. There are updates on our own in both the ALS and Progressive MS programs that I want to cover today, as well as some important additions to our management team. First, With regard to our lead program, Neuron and ALS, we remain committed to advancing this program and pursuing the best and most expeditious path forward to enable patient access. Patients and advocates are changing the landscape of ALS to match the urgency of their disease. Given the important changes, we are in active dialogue with regulators around our regulatory plan and we will share this as soon as it is appropriate. We recently presented important new biomarker data from our Phase III trial in ALS in a poster session at the Northeast ALS Consortium for NILS in October. The presenter was Dr. James Berry, the Principal Investigator of Neuron Trial and the Director of the Massachusetts General Hospital Multidisciplinary ALS Clinic. Biomarker analysis, as a reminder, were pre-specified in the statistical analysis plan and was completed and submitted to the FDA prior to unblinding of the tract. These involved collecting PSF samples from all participants and measuring pre-specified biomarkers at seven time points from baseline through week 20. The results of these analysis showed that neural treatment resulted in significant changes across many biomarkers pertaining to neurodegeneration, neuroinflammation, and neuroprotection, while levels of these biomarkers remained stable and unchanged following treatment with placebo. Another important analysis that was pre-specified was designed to help us understand how the observed changes in biomarkers with neuron related to clinical response observed in the trial. As shared in Daniil's presentation, Dr. Berry presented results from a stepwise regression model which identified a set of biomarkers spanning the pathways of neuroprotection, neuroinflammation, and neurodegeneration biomarkers that accurately predicted clinical response in the trial with over 80% accuracy. And not only did we observe significant changes in biomarkers important for ALS with neurons, but they are meaningful in helping us understand who responded to treatment in the studies. The results further our understanding of neurons' mechanism of action in ALS, which targets multiple pathways and provides additional evidence linking the mechanism of action to neurons' impact on ALS disease progression. In the future, this information will also help future studies that use CSF biomarkers to advance ALS science. We do, of course, plan to share them with the FDA and other regulatory authorities. A hyperlink to this poster was included in the press release, which is available on the publication section of the Brainstorm website. I would encourage investors to review it. Turning now to our Progressive Multiple Fetorosis Program. The results from our Phase II study of Luron in Progressive MS were featured in an oral presentation at the 37th Congress of the European Committee of Treatment and Research in Multiple Fetorosis, or ACTRAN. We announced positive top-line results from the study in March of this year, and this was our first opportunity to share the results with the broader neurology community at a major international MS meeting. The presentation was given by Dr. Jeffrey Cohen, the director of experimental therapeutics at the Cleveland Clinic Mellon Center for MS and Principal Investigating the Neuron MS Phase II Trial. Dr. Cohen shared that the study achieved its primary endpoint of safety and vulnerability. In addition, we demonstrated a reduction of neuroinflammatory biomarkers and an increase in neuroprotective biomarkers in CSF. In addition, we observed consistent improvement across MS-functional outcome measures, including walking, upper extremity function, vision, and cognition. Brainstorm was the main sponsor for this study, but we had additional financial support for the biomarker analysis from the National Multiple Sclerosis Society's Best Forward Program.
spk11: We are actively
spk12: working on a development plan in order to advance the progressive MS program through registration and approval. We are currently holding discussions with CMS experts and seeking guidance from the FDA to determine X steps. We have submitted a manuscript summarizing the trial results for publication. Grainsome is developing an innovative exosome-based platform technology which utilizes exosomes derived from neurons. We have been exploring acute respiratory distress syndrome, or ARDS, as a potential first indication. Our preclinical data from this program were published in the journal Stem Cell and Research Therapy at the beginning of the year, and Dr. Ravital Arika, Vice President of R&D, had an opportunity to present this data at the New York Stem Cell Foundation's 2021 virtual meeting, which took place in October. The results showed that neuron exosomes were capable of increasing blood oxygen saturation and reducing lung pathology, inflammatory infiltrates, and levels of pro-inflammatory cytokines in two animal models of ARDS. We showed that neuronexinals were superior to naive MSEs, exosomes, and all examined parameters. Finally, I want to mention some important additions to the management team and to the board of directors. We announced last week that we had appointed Dr. Sidney Spector as Senior Vice President, Global Strategy and Medical Affairs, and Dr. Kim Tacker as Senior Vice President, Medical Affairs and Clinical Innovations. Dr. Thacker was most recently Clinical Associate Professor of Neurology at the University of Arizona, College of Medicine, and worked in the industry developing CNS drugs at Novartis, Elan Pharma, and Pfizer. Dr. Thacker brings more than 20 years of experience at Pharma and Biotech, most recently at Sanofi Medical Affairs at URGEN, and previously at Sanofi Ventis, Pfizer, and Roche, among others. Both Dr. Thacker and Dr. Thacker will work together to create a formal global medical affairs function, as we prepare for anticipated growth. In addition, we expanded the responsibilities of Dr. Stacey Lindbergh, executive vice president of the new position of chief development officer. In this role, she will build the leadership team for development and regulatory affairs to support clinical development in multiple disease areas and technologies. We also recently announced that Dr. Menges Bayrou was appointed to the board of directors in October. Dr. Bayrou is a physician entrepreneur, business executive, editor, author, and philanthropist. He is founder, chairman, and CEO of Praxenia Venture Partners, which provides capital, talent management, and access to a global network of experts to companies on late preclinical and early stage clinical development devices. He's also chairman and CEO of Biorex and International Medical Education, a market research organization focused on Africa and the Middle East. At this critical juncture in the history of brainstorm solver projects, These appointments will expand the leadership team with capabilities that complement our already strong team and help us as we advance our development portfolio of innovative treatments. I want to formally welcome Sydney Kim and Mengis to brainstorm and congratulate Stacey on her new responsibilities.
spk11: I will now turn the call over to Alep Patlis, who will review our financials.
spk09: Thank you, Hans.
spk08: It's my pleasure now to walk you through our third quarter 2021 financial results. Brainstorm's cash, cash equivalent, and short-term bank deposits were approximately $38 million as of September 30, 2021, and this compares with approximately $35 million on June 30, 2021. Research and development expenses for the three months ended September 30, 2021 and 2020 were approximately $3.6 million, and 4.1 million, respectively. Research and development expenses net for the third quarter of 2020 was 1.9 million, which includes participation from IAA and other grants. General and administrative expenses for the three months ended September 30, 2021 and 2020 were approximately 1.7 million and 2.6 million, respectively. Net loss for the three months ended September 30, 2021 was approximately $5.3 million, or $0.15 per share, as compared to a net loss of approximately $4.5 million, or $0.14 per share, for the three months ended September 30, 2020.
spk09: Back to you, Chaim.
spk11: Thank you so much, Alla. Mike, would you please read now the questions we have received from investors?
spk13: Yes, the first question directed at you, Jaime. What do you say to those who state that you have ethical obligation to make Neuron available now for ALS patients? Do you feel that the phase three trial met a high ethical standard? And do you think most patients with ALS would agree with you?
spk12: Thank you, Michael. We hear and understand the urgency expressed in this question. because we hear an urgency every day directly from patients and through social media for access to Neuron. This is a complicated question with lots of dimensions. Let me start by acknowledging that broad access to Neuron at this point in the development cycle can only come through a regulatory approval. However, we engaged with regulators and took action to establish a small EAP, expanded access program, which demonstrates our urgency to make Neuron available beyond the completion of the Phase D trial. We treated the maximum number of patients we were able to do with the company's resource limit. The FDA gave its full support for the EAP, and the dosing for this protocol has now been completed. And this will provide additional data into the effect of Neuron-based on a longer treatment period. And while we haven't released any data from this program, Dr. Merit Suskowitz testified at the recent ALS professional hearing, and I quote, there are reports from people in the neuron trial and expanded access program of improvements in function, not something we typically see or hear in ALS.
spk11: End of quote. We are excited to see what we will learn from this program.
spk12: Returning to the component of your question that inquires about brainstorms ethical obligation, there's no question in our minds that this trial meets an extremely high ethical standard even though enrolling a population more representative of the ALS community than most ALS trials made it more challenging to conduct the study. We truly believe in the effectiveness of Neuron, and we're working urgently to provide it to those who could benefit, even as we continue our research to learn more. As we noted in our earlier remarks, we have submitted the full data set for publication in a peer-reviewed journal and expect to be able to share these results widely upon publication.
spk11: We sincerely hope the people and families living with ALS know that we have their best interest in our heart. Next question, please.
spk13: So what is the status of the neuron application to the FDA? Will the application be submitted or considered early?
spk12: Stacy, would you take this one, please?
spk04: Sure. We've been clear in our communications over time that before we would make a decision around the filing of a BLA application of neurons, that we intended to first publish the results from our trial in a peer-reviewed journal, and second, to meet with important members of the ALS community who were not involved in the conduct of our phase three trial. As I just shared on this call, we've made great progress with these goals, and immediately after the publication is in print, we will be prepared to speak to our plans for BLA filing.
spk11: Thank you.
spk13: Next question, please provide an update on the identification of ALS biomarkers.
spk12: Stacy, it's your turn.
spk04: Sure. So, in the phase three trial, we generated a unique set of biomarker data through the collection and analysis of seven CSF samples over time going from baseline to 20 weeks in all study participants. And as Haim just reflected, we observed significant improvements in multiple CSF biomarkers of neuroinflammation, neurodegeneration, and neurotrophic factor support with neurotreatment, while placebo remained unchanged and stable. A few examples, so for, and all of these are at week 20, which is the final time point that we collected biomarker data on. With VEGF, which is a marker, an important marker of neuroprotection, we observed a two-fold increase with neuron-treated patients while placebo remained unchanged. With MCP1, a marker of neuroinflammation, the values were 74% with neuron-treated patients of placebo, which was a remarkable reduction over the placebo values. Finally, neurofilament light, A marker of neurodegeneration was 84% of placebo values in neuron-treated patients at that last time period. As we shared in our prepared remarks, Dr. James Berry, principal investigator from Mass General, recently presented the results of a stepwise regression model at Niels, which identified a set of biomarkers spanning these really important pathways of neuroprotection, neuroinflammation, and neurodegeneration. And this model accurately predicted the primary clinical response, our primary endpoint in the trial, with over 80% accuracy. So not only are there changes observed in these important biomarkers for ALS, but they're meaningful in helping us understand who responded to treatment in the study. So in summary, our detailed biomarker analyses support the proposed mechanism of action of neurons and provide additional evidence linking the mechanism of action to neurons impact on ALS disease progression. And a thorough analysis of this data will be published separately in a peer-reviewed manuscript.
spk12: Thank you so much.
spk13: So the next question relates to the earlier clinical and pre-clinical programs. Please provide an update on the trials and data associated with MS and Parkinson's disease. Thank you. Ralph?
spk10: Yeah, thank you for the question, Michael. I'll start with our MS program. As you recall in Heim's prepared comments, the MS Phase II clinical trial was completed earlier this year, and the data was recently presented in an oral presentation of the 37th ECTRIMS Congress by Dr. Jeff Cohn from the Cleveland Clinic. The high-level summary was that the study achieved the primary endpoint of safety and tolerability. It also demonstrated a reduction of neuroinflammatory biomarkers and an increase of neuroprotective biomarkers in the cerebrospinal fluid, as well as consistent improvement across MS functional outcome measures, including measures of walking, upper extremity function, vision, and cognition. We're now holding discussions with key MS experts and seeking guidance from the FDA to determine next steps. As mentioned earlier, we've also submitted a manuscript for peer review and publication. I'll now address the question about Parkinson's disease. As you know, Parkinson's is a disease that we remain quite interested in. We believe neurons demonstrated mechanism of action could motivate this as a future clinical target. But for now, we don't have an update on this indication. To date, our clinical priorities have been focused on first, ALS, second, progressive MS, and third, Alzheimer's disease. And given our size as a company and the resources we can bring to bear on all our work, we're being very careful to not move too quickly with other indications. Thank you.
spk13: And then regarding Alzheimer's and ARDS, can you provide updates here, please?
spk10: Absolutely. So regarding Alzheimer's, in the Q2 earnings call, we shared that with the recent approval of Aduhelm and with other advances in the Alzheimer's disease competitive landscape, that we wanted to step back and strategically consider our clinical goals before proceeding with the clinical study in Alzheimer's disease with Neuron. Alzheimer's disease remains a prioritized indication, and as such, as we've already engaged with a few of the top Alzheimer's KOLs in the US and have shared our data with them, we've been consulting with them on our clinical plans. Their feedback has been exciting and very helpful. We also expect to have an update to share publicly very shortly. And finally, regarding ARDS, Chaim made a very full description of our results. What I can add is that as we shared earlier, we've demonstrated the beneficial effects of our derived exosomes and acute lung injury model. In addition to demonstrating a superior effect of these exosomes compared to naive MSCs, All of these results, including the publication in Stem Cell Research and Therapy Journal, are available on our website. We've continued to do further research using a bleomycin model of lung injury, which is characterized by extensive inflammation, fibrosis, and injury to the lung tissue. And we look forward to sharing new insights, including how they fit together with our priorities going forward. Thanks so much.
spk13: And then finally, we have one question relating to business development. Please provide an update on the plans for joint ventures or partnerships with other companies. David?
spk02: Sure. So, partnering is an integrated part of our strategy. We are actively engaging with a variety of potential partners, which includes midsize and leading pharmaceutical companies. And we are engaging for both Neuron ALS, NMS, and as well, a more recent Exosome program. Thank you.
spk12: Sure. Paul, would you open the line for questions from investors on the line?
spk01: Certainly. Ladies and gentlemen, the floor is now open for questions. If you have any questions or comments, please press star 1 on your phone at this time. We ask that while posing your question, you please pick up your handset if listening on speakerphone to provide optimum sound quality. Once again, please press star one if you have a question at this time, and please hold while we poll for questions. And the first question is coming from Jason McCarthy from Maxim Group. Jason, your line is live.
spk03: Hey, thanks for taking my question. This is Michael Okunowich on the line for Jason. So her first question, I'd like to gauge your thoughts on the Exosome platform and how that might best be applied, whether it could be thought of as, you know, a next-gen follow-up in indications where Neuron is already successful, or if it's more targeted towards indications which may have an increased benefit from using what is essentially a snapshot of the signaling activity of the cells.
spk12: Thanks, Michael. Ralph, you want to take this question?
spk10: Yeah. Thank you for the question. Yeah, we view exosomes as potentially next generation, but I think that there are some unique advantages of exosomes that are worth mentioning. First of all, the ease of formulation. and logistics are definitely an advantage, including potentially, you know, cost. There are unique advantages of exosomes in terms of delivery in certain unique situations. You know, for example, in the lung, sending products through the airways that are very small, the size of viral particles like exosomes, is very advantageous to reach the most distant parts of the lung. So there are some biophysical reasons why we have applied that in the lung, particularly in the acute lung injury model. There are still questions around exosomes that we're working on, and we intend to leverage the preclinical knowledge to make a best decision about the optimal application of exosomes both in lung disease and potentially in other diseases as well.
spk03: All right, thank you. And then I'd like to follow up on that. Just have you given any thought as to how you might formulate the exosome platform for delivery to the lungs? Like we use nebulization or dry powder. Have you given any thought to that for when it eventually might move into humans?
spk12: Yes, so I will take that. Definitely, we gave a lot of thought, and we're looking at the different pathways, and you mentioned those pathways, and inhalation is definitely something we're looking at or interested to take. But yes, when we'll get into humans, we'll have to take that decision. We're doing preclinical trials in order to confirm the best way of target. A very good question. These are one of the major questions on exercise, right? And just to add, of course, for the CNS space, Exosomes also may be beneficial for diseases like Parkinson's, mentioned before, as it probably can overcome developing barrier issues.
spk11: Thank you very much.
spk03: And then just one more on the biomarker data. I wanted to see if you could provide a bit more color on how you could leverage the biomarker data and its correlation to outcomes in your discussions with regulators and your further development within ALS.
spk12: Thank you very much. I'll let Stacy answer that.
spk04: Yeah, I'm happy to respond to that. Thank you. Well, as Haim already described in his prepared remarks, you know, these were pre-specified analyses and were submitted to the FDA before we unblinded our trial. So, you know, these kinds of models, which are really important, the fact that they're pre-specified, of course, these will become part of, of discussions with regulators as we progress either with informal discussions or formal discussions as they proceed. The important part of the model that Haim described to you is that it really leverages the relationships observed in the data, and it's machine learning in the sense that it doesn't involve our judgment or kind of preconceived beliefs about biomarkers. It doesn't allow that to interfere. This model that Haim was just speaking about really is harnessing the information, what we've observed about the treatment effects on these important biomarkers, and they're selected into this model to help provide the most accurate explanation or prediction of the patients that responded.
spk12: Thank you very much for taking my questions. Yes, thanks so much, Michael. Next question, please.
spk01: Thank you. And the next question is coming from David Bouts from Zach's Small Cap Research. David, your line is live.
spk07: Hey, good morning, everybody. So my first question is about MS. So clearly there's a lot of MS drugs that are out there right now. And now that you've got some data in hand, I'm curious what your thoughts are on where Neuron might fit in that treatment landscape.
spk10: Look, the current Yeah, David, thank you for that question. I think it's worth just describing again the unmet need in progressive MS. As you know, most of the therapeutic success in MS has been for relapsing remitting MS, and it's been remarkable over the past 20 years how well that's gone. There still is a very large unmet need in progressive MS, both clinically. Patients continue to deteriorate slowly despite the use of the optimal and most recent successful treatments. And also there's an unmet biologic need. We think that that's what we're targeting in terms of the compartmentalized inflammation in the brain, delivering the treatment directly into the spinal fluid and changing the microenvironment and also delivering repair molecules and neurotrophic factors. We think that's what we saw in our phase two trial. We're very excited about the results. There's huge potential and a lot of interest among experts and also among international organizations to see what the next steps might be. So we're carefully considering all that. We're very optimistic about where we go next, and we want to consider that carefully, receive the feedback from the agency, obviously, and other regulatory bodies, and then make the best decision about what the next steps will be. And we'll have an announcement once we've gotten there. So thanks for that question again.
spk07: Okay, thanks for that. And I did have one question about the ALS biomarker data. I just want to make sure that I understand. So of those biomarkers that were identified, was each of them correlated to outcome of neuron treatment, or was it the biomarkers as a group?
spk12: I know, David, that an analyst will come up with a question understanding the correlation in the group and the models. We have an expert on the line, Dr. Stacy Lindbergh. It's all yours.
spk04: Thank you. So to provide maybe a little bit more clarity into the methodology again. So all biomarkers that were collected as part of the study were possible to be included in this model. So the methodology allowed any of these biomarkers that were contributing an explanatory value towards this prediction to enter the model. And for anyone marker to come into the model, it had to be statistically significant at a level of a p-value less than 0.05. And to remain in the model, it also had to remain statistically significant, so with a p-value less than 0.05. So these kinds of iterative models basically allow terms to come and go and then ultimately to land on the optimal model that has the strongest prediction. All of the terms, all of the biomarkers that are part of it, which of course were reported in the poster at the MEALS meeting recently, are contributing simultaneously significant information towards this prediction. And Haim spoke of the accuracy. So what we presented in this poster is an area under the curve. It's coming from a receiver operating characteristic. And it really gives us, it's a wonderful metric, it's a diagnostic metric that allows us to evaluate how accurate the prediction is, or in this case, how good these biomarkers are in discriminating participants that responded in the trial versus those that didn't. And as a rule of thumb, if you have above 80%, this is quite high classification. And in our model that we spoke of and what we reported on at Neal's, we had an area under the curve from the receiver operating curve of 82.5. And we actually see this estimate increase when we focus on models that are predictive of each therapy separately. And this will be the focus of our biomarker paper that we will be hopefully submitting in the near future.
spk12: David, I'm sure you would like to understand more, I think, on this. We're going to have an offline conversation with Dr. Lindberg. I'm not sure all investors are following these models, right?
spk07: Okay. No, that's fine. And then I have one more. Last quarter you mentioned that the hospital exemption program was currently not ongoing in Israel, and I'm just curious if there's similar type programs being planned for other jurisdictions.
spk12: I'll give you a short answer, yes. I can't elaborate.
spk07: Okay. Fair enough. Thanks for taking the questions.
spk01: Thank you. Ladies and gentlemen, once again, if you wish to enter the queue to ask a question, you can please press star 1 on your phone at any time. And the next question is coming from Paula Smith. Paula, your line is live.
spk06: Good morning. First, as a mom, I just wanted to express my gratitude to Brainstorm. I'm just so grateful that My son was given the opportunity to be in the trial and that brainstorm is just giving us hope and access to a treatment for ALS and that hopefully we can continue it. I just wanted to say my son is 32 years old and he's been in the Phase III trial and in the Expanded Access trial. While he was in both, he stabilized, he regained function, and his ALS-FRS score had improved. So the biggest improvement for Josh was his FVC had improved to over 40%, which to me is amazing. He's still able to walk. He can still climb stairs. He can still get into his Jeep. He can eat. He has no problem swallowing. And he's still able to use his hands. And this is four years from his onset. Our doctors here all believe that Neuron works and we are in close contact with other people that are receiving the EAP and their experiences and how they stabilized. So my question is, can you speak about the results in EAP now that everyone has received the three doses and will Brainstorm be using the EAP data to speak and seek approval for Neuron.
spk11: So Paula, thank you for your question.
spk12: I wasn't expecting this. I thought it's a private investor. As you know, we are not yet, and as we said in the comments at the beginning of the call, we cannot yet talk to the AP results. Very warming to hear what you are saying and you're describing. And I do hope that we should be able to share with you some good news very soon. That's all I can say for the time being. And I'm very happy that your son is doing well and is being stable or even better.
spk06: It is. It's amazing to me. It's a miracle. And I just wanted to continue.
spk11: Well, we all want the same. You know, we're working very hard at that. Thank you. You're very welcome.
spk01: Thank you. And the next question is coming from Michelle Lawrence from Voices for ALS. Michelle, your line is live.
spk00: Thank you. Hard to follow up after Paula. Last month at ECTRIMS when Dr. Cohen from Cleveland Clinic spoke about the results in progressive MS, I found it quite profound because he used the words that neuron repaired and restored function. And he did that in an interview with Neurology Live. And it struck me that those words mirrored what the patients had been saying in the neuron trial since 2015 back in phase two. So those words are subjective. What I want to know is if you can speak to any of the similarities in the biomarker data between the MS study and the ALS studies. and if any of that biomarker data from one or the other helps validate the evidence of efficacy in the other disease.
spk12: Thank you. Very good question. I will allow both Ralph and Stacey to comment on this because there are different aspects to this question to answer.
spk10: Ralph? Sure. I'll start and hand off to Stacey. So thank you again for that really insightful question. The answer is yes. But I think it requires some explanation. And we'll start today and maybe we can take this offline. There are two main areas where we observe significant biomarker changes. And Stacy gave a very clear and detailed description of that a few minutes ago. Just to highlight a couple of points. One is that in the area of neuroprotection, this is something that is deficient in ALS and also in progressive MS. as it is in many neurological diseases where the repair mechanisms are failing. And that's part of the known disease processes. We believe that repairing the nervous system requires restoring this neuroprotection function. And we know that the cells that we have primed in our technology platform are able to do that. better than unprimed MSCs and certainly better than other therapies because that's a prime function of the cells is to deliver these molecules. The second area is inflammation. We know that literally every day there's more data suggesting that all neurodegenerative diseases have inflammation. There's slight differences in terms of which cells participate and how it influences the outcomes, but we know that there's a big commonality between ALS and progressive MS regarding the inflammatory pathways. And again, there we see consistent changes in inflammatory biomarkers. The advantage of looking at CSF or cerebrospinal fluid is that we get a direct view of what's happening in the brain microenvironment. So, I'll pause there and I'll hand off to Stacey to answer the other parts of the question.
spk04: Well, Rafa, you covered this, I think, extremely well in terms of really linking not only what we believe about the deficits that are known across neurodegenerative diseases in known biomarkers and the similarities of what we're observing with neuron across these two devastating illnesses. I think the point that I would add is that, you know, anytime we're looking at why we believe a treatment is working. And of course, biomarker data is critical across all diseases and giving us insight into biologically what's happening. One of the important aspects has been to understand also the treatment relationship with clinical symptoms. And in your question about are we seeing similar repair and function restored, this is also a component that is extremely important. In the progressive MS trial, we had responder criteria that showed that patients were improving in their clinical function across, you know, many of the known clinical measures which Ralph enumerated before. Similarly, we can observe in our ALS data and, of course, the formal analyses that we've done really linking biomarkers and clinical data also show this important link that not only do we see important changes either slowing down the decline or in some cases improving decline, but we see similarly that the biomarkers are going in the direction that one would expect with ineffective treatment. So we're seeing reductions in neuroinflammation and we're seeing improvements in neuroprotection. So I think it's a very insightful comment and and a really great question for us to continue to consider.
spk11: Thank you.
spk01: Thank you. And there were no more questions in queue at this time. I would like to hand the call back to the Brainstorm Cell Therapeutics Management Team for any closing remarks.
spk12: Thank you, Paul. No further remarks. Thank everyone for listening in. Looking forward to a very exciting quarter. Good luck, everyone.
spk01: Thank you, ladies and gentlemen. This does conclude today's conference. You may disconnect at this time and have a wonderful day. Thank you for your participation.
Disclaimer